OrbiMed Advisors LLC, along with its affiliated entities OrbiMed Genesis GP LLC and OrbiMed Capital GP VII LLC, has reported the sale of Enliven Therapeutics, Inc. (NASDAQ: ELVN) common stock. The total value of the divestment reached approximately $39,014,045. These transactions were executed on June 22, 2026, marking a significant reduction in the firm's holdings.
According to the filing, the investment entities disposed of a total of 860,123 shares. The shares were sold at prices ranging from $45.00 to $45.38 per share. This divestment occurs as Enliven’s stock trades near its 52-week high of $49.94, following a remarkable 210% year-to-date surge. The stock's recent performance has drawn attention, with current trading activity reflecting the volatility and momentum characteristic of biotech equities during periods of rapid appreciation.
Analysis from InvestingPro suggests that Enliven’s stock currently appears overvalued relative to its fair value. This finding may provide context for the timing of OrbiMed’s sale, as investment decisions in the biotech sector often hinge on valuation metrics and market sentiment. The company carries a market capitalization of $2.96 billion, reflecting the scale of its operations and the confidence of the broader market in its growth trajectory.
The filing indicates that OrbiMed Advisors LLC, OrbiMed Genesis GP LLC, and OrbiMed Capital GP VII LLC are considered ten percent owners of Enliven Therapeutics. The securities are held indirectly through various funds. Some securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"), with OrbiMed Genesis GP LLC as its general partner and OrbiMed Advisors LLC as the managing member of Genesis GP. Other securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"), where OrbiMed Capital GP VII LLC ("GP VII") acts as the general partner and OrbiMed Advisors is the managing member of GP VII.
Following these transactions, the OrbiMed entities collectively hold 6,774,507 shares of Enliven Therapeutics common stock. The reporting persons disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest. This structure highlights the complex ownership arrangements common in institutional investment vehicles, where control and economic interest are distributed across multiple legal entities.
In other recent news, Enliven Therapeutics Inc. has successfully closed an upsized public offering, generating approximately $460 million in gross proceeds. This follows the company’s initial pricing of a $400 million public offering at $37.50 per share, with an additional option for underwriters to purchase more shares. The company had earlier announced a $250 million stock offering, indicating a series of strategic financial moves to bolster its balance sheet.
Enliven Therapeutics also reported positive Phase 1 trial results for its leukemia drug candidate, ELVN-001. The trial demonstrated a 61% overall major molecular response in patients with chronic myeloid leukemia. The updated data from the ENABLE trial further highlighted a 48% major molecular response achievement by 24 weeks in the 80 mg once daily Phase 1b cohort. The trial included 161 patients, most of whom remain on study with a median treatment duration of 35 weeks. These developments reflect significant activity and progress in Enliven Therapeutics’ financial and clinical operations.
Enliven Therapeutics stock closed at $47.77, down $0.830 or 1.71%. After hours trading saw the stock at $47.081, down $0.689 or 1.44%. The stock's performance underscores the dynamic nature of the biotech sector, where clinical data and financial news can drive significant price movements.